press release - Page 26 - Pappas Capital

The Wistar Institute Welcomes Three New Board Members

PHILADELPHIA—(November 16, 2012) – The Wistar Institute recently welcomed Van Billet, Joseph Goldblum and Art Pappas to its board of trustees.

Art Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. Currently, he serves as managing partner at Pappas Ventures, a life sciences venture capital firm with more than $300 million in capital under management. The firm has invested in over 50 biotechnology, biopharmaceutical, specialty pharmaceutical, drug delivery and medical device companies throughout the U.S.

Uncategorized - 11/16/2012

Chimerix Appoints Michelle Berrey Chief Medical Officer

RESEARCH TRIANGLE PARK, NC, November 12, 2012 — Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Michelle Berrey, MD, MPH, has joined the company as Chief Medical Officer.

"We are delighted to have Michelle join our leadership team. Dr. Berrey is a seasoned drug developer who has established a strong track record in antivirals, in particular with nucleotide analogs. She joins Chimerix at an important time for the company as our lead compound, CMX001, advances into Phase 3 clinical testing,” said Kenneth I. Moch, Chimerix President and Chief Executive Officer. “Her extensive background in antiviral drug development will be invaluable to our already strong team.”

Chimerix - 11/12/2012

TYRX(R) Receives Health Canada Approval

MONMOUTH JUNCTION, N.J., Oct 04, 2012 (BUSINESS WIRE) -- TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, announced today that it has received a license from Health Canada to market its AIGISRx Antibacterial Envelope. The AIGISRx Envelope is specifically designed to stabilize pacemakers and implantable defibrillators while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.

TYRX - 10/04/2012

FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medical Device and Diagnostic Companies of 2012

Monmouth Junction, NJ – (October 2, 2012) – TYRX, Inc. announced today that it has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.

FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their top management teams, notable financial backing, and promising technologies and market opportunities. TYRX was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.

TYRX - 10/02/2012

CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most Promising Private Companies

PALO ALTO, Calif. – Oct. 2, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company has been named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world. FierceMedicalDevices editors chose this year's winners based on their top management teams, notable financial backing, promising technologies and market opportunities. The award was presented today at an event that took place during AdvaMed 2012: The MedTech Conference in Boston, Mass.

CardioDx - 10/02/2012

TYRX® Comments on Medicare Decision to Stop Paying for Infections Following Pacemaker or Defibrillator Implants Release

Monmouth Junction, NJ (August 2, 2012) - In a bid to help control health care costs, on October 1, 2012, the Centers for Medicare and Medicaid Services (CMS) will stop paying hospitals for treating potentially avoidable surgical site infections following Cardiac Implantable Electronic Device (CIED) procedures including pacemaker and defibrillator implants. CMS just released its Hospital Inpatient Prospective Payment System (IPPS) Final Rule for Fiscal Year 2013 which adds Surgical Site Infection following CIED implantation as a condition subject to the Hospital Acquired Condition payment provision. CMS considers these infections to be reasonably preventable and has classified them as complicating conditions that would otherwise result in higher payment to the hospital. Under the new policy, CMS will pay for the original surgery, but will not reimburse hospitals at a higher rate for treating the infection.

TYRX - 08/02/2012

Liquidia Technologies Inc. Studies Show PRINT® Engineered Particles Hold Promise in the Delivery of Respiratory Therapeutics

RESEARCH TRIANGLE PARK, N.C.-May 12, 2012-(BUSINESS WIRE)--Liquidia Technologies today announced the results of two newly-released studies that illustrate the unique benefits of the company’s proprietary PRINT® (Particle Replication In Non-Wetting Templates) platform in the development of advanced respiratory therapeutics. Despite the high prevalence of lung disease, optimizing critical parameters of respiratory therapeutics to improve their pulmonary distribution and effectiveness has remained a challenge for the biopharmaceutical industry. These studies demonstrate how the PRINT platform can be used for respiratory drugs by precisely engineering particles with controlled shape, size, and chemistry, all characteristics that could lead to better lung delivery and therapeutic performance. Aspects of these findings were published in the Journal of Drug Delivery and presented at the Respiratory Drug Delivery Conference being held May 13-17, 2012 in Phoenix, Arizona.

Liquidia Technologies - 05/15/2012

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

NOVATO, Calif., May 1, 2012 /PRNewswire/ Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration. UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM, a severe, neuromuscular disease caused by sialic acid deficiency. Based on the Phase 1 results, Ultragenyx plans to initiate an international, multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 2 study of UX001 in HIBM patients in the second quarter of this year.

Ultragenyx Pharmaceutical - 05/01/2012

CardioDx Honored as 2012 Gold Edison Award Winner

Corus CAD Wins at the Edison Awards Gala; Awards Celebrate 25 Years of Honoring Innovators and Innovation

PALO ALTO, Calif. – April 30, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Corus® CAD has been honored as a gold winner in the Science & Medical category of the internationally-renowned 2012 Edison Awards. The awards, which were presented last week at a gala in New York, symbolize the innovation personified by Thomas Alva Edison, inspiring America’s drive to remain at the forefront of creativity and ingenuity in the global economy.

CardioDx - 04/30/2012

LipoScience Receives 2012 Diagnostic Marketing Association Creative Communications First Place Award

NMR LipoProfile® test campaign communicates importance of LDL-particles in cardiovascular disease risk and management

RALEIGH, N.C.- April 26, 2012 (BUSINESS WIRE) -- LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced that it has received first place recognition at the 2012 Diagnostic Marketing Association (DxMA) Creative Communications Awards for the integrated print and online category for LipoScience’s NMR LipoProfile® test campaign.

The award was presented at the 2012 DxMA awards reception on April 25 in Chicago. The DxMA recognizes excellence in diagnostics marketing, advertising and promotional programming. LipoScience partnered with Motivation Mechanics, a Philadelphia-based marketing research and communications strategy firm, on the campaign.

LipoScience - 04/26/2012